5 completed, 2 terminated, 1 suspended, 1 withdrawn. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Terminated 2, Suspended 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
Follow CYT003-QbG10: new trials by email Literature Review of CYT003-QbG10 trials Research Report on CYT003-QbG10
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer VLP-encapsulated TLR9 Agonist CMP-001,, Nivolumab - Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 | Phase 2 | Suspended | Emory University | 10 | 2023-06-07 | 2026-10-13 |
| CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001 - Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Terminated | University of Southern California | 2 | 2021-04-29 | 2026-04-17 |
| CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids CYT003, Placebo - Asthma | Phase 2 | Withdrawn | Cytos Biotechnology AG | 2014-05-01 | 2014-05-14 | |
| CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma CYT003, Placebo - Moderate to Severe Allergic Asthma | Phase 2 | Terminated | Cytos Biotechnology AG | 365 | 2012-11-01 | 2014-05-14 |
| CYT003-QbG10 for Treatment of Allergic Asthma Bronchial CYT003-QbG10, Placebo - Allergic Bronchial Asthma | Phase 2 | Completed | Cytos Biotechnology AG | 63 | 2009-04-01 | 2012-02-13 |
| Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy CYT003-QbG10, Placebo - Rhinoconjunctivitis, Allergies | Phase 2 | Completed | Cytos Biotechnology AG | 300 | 2008-11-01 | 2010-11-15 |
| Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis CYT003-QbG10 - Perennial Allergy to House Dust Mite and/or Cat | Phase 2 | Completed | Cytos Biotechnology AG | 64 | 2007-12-01 | 2009-04-27 |
| A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10), House dust mite allergen extract in combination with CYT003-QbG10-placebo - Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy | Phase 2 | Completed | Cytos Biotechnology AG | 100 | 2007-11-01 | 2009-04-27 |
| A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10), House dust mite allergen extract in combination with CYT003-QbG10-placebo, CYT003-AllQbG10 in combination with house dust mite allergen extract placebo - Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy | Phase 2 | Completed | Cytos Biotechnology AG | 40 | 2006-09-01 | 2013-07-11 |
Dust Mite Allergy (2) · Asthma (1) · Hypersensitivity (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Cytos Biotechnology AG (7) · Emory University (1) · University of Southern California (1)
United States (4) · Germany (3) · Estonia (2) · Latvia (2) · Lithuania (2) · Czechia (1) · Greece (1) · Hungary (1) · Israel (1) · Poland (1) · Romania (1) · Russia (1) · Switzerland (1) · Ukraine (1)
Philipp Mueller, MD (2) · Audra Blaziene (1) · Diana L Hanna, MD (1) · Mehmet A Bilen, M.D. (1) · Thomas B Casale, Professor (1) · Thomas Casale, MD (1)
P30CA014089 (1)